Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.

Trial Profile

Bevacizumab administered intraperitoneally as palliative treatment of malignant refractory ascites.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Antineoplastics
  • Indications Malignant ascites
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2015 Assumed phase chosen as II rather than IV as bevacizumab was not approved for peritoneal cancer indication in EU until Aug 2014. Formulation is perfusion, but this is not listed in available formulations for CT.
    • 01 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top